• About Us
    • Overview
    • Senior Team
    • Board of Non-Executive Directors
    • Investors & Shareholders
  • Our Technology
  • Pipeline
  • NephroScan®
  • News & Events
    • Press Releases
    • In the News
    • Events
    • Publications
  • Careers
  • Contact
  • Menu Menu

About Us

Board of Non-Executive Directors

Eduardo Bravo

Chairman

Eduardo Bravo is CEO of Dutch biotech company, Cytrill, and has held many leadership positions in the biopharmaceutical industry over the last three decades. Until March 2023 he was the CEO of EBAC, a Nasdaq listed SPAC sponsored by LSP that merged with Oculis, a European biotech company focused on ophthalmology.

In his 30 years of senior management and board experience, Eduardo has been CEO of Nordic Nanovector, TiGenix and Cellerix, and before that held several senior management positions at Sanofi-Aventis and SmithKline Beecham. As CEO of TiGenix, he oversaw several financing rounds, the company’s IPO on Nasdaq and its eventual acquisition by Takeda in 2018.

Eduardo is currently Chairman of the Board at Vivet Therapeutics and Engitix Ltd and he was President of the European Biopharmaceutical Enterprises Board of Directors between 2016 and 2018.

Ariceum Therapeutics

Olivier Litzka, PhD

Non-Executive Director

Olivier Litzka is a Partner at Andera Partners and a Director of the Board of Ariceum. Olivier has a Ph.D. in molecular microbiology from the LMU in Munich. He started his business career in 1998 with Mercer Management Consulting. In 2000, Olivier joined 3i Group plc with a focus on biopharma and medtech investments, first based in Munich, later in 3i’s Paris office.

In 2006, Olivier joined as a partner Andera Partners’ BioDiscovery team and contributed to grow the company to one of the leading Life Sciences Venture Capital investors in Europe. Olivier was on the board of multiple companies which got acquired or went public. Currently he is involved in several biotech and medtech startups in Europe and the U.S.

Ariceum Therapeutics

Christoph Massner, PhD

Non-Executive Director

Christoph is a Principal at the Earlybird Venture Capital Health Fund, which he joined in 2018. Earlybird Health invests in European health companies across the sectors of biopharma, medical devices, diagnostics & platform technologies and digital health. Currently, he serves as a board director of wellabe and as a board observer of Alesi Surgical. Before joining Earlybird, Christoph conducted research in different laboratories in Germany and Australia for +7 years.

Christoph graduated in Technical Biology from the University of Stuttgart and holds a PhD in Synthetic Biology from the Technical University of Munich.

Ariceum Therapeutics

Joachim Rothe, PhD

Non-Executive Director

Joachim (JR) Rothe is a Partner in the EQT Life Sciences team. JR was Managing Partner at LSP from 2001 until 2022, when LSP joined forces with EQT and was renamed EQT Life Sciences. Prior to joining LSP, JR worked in a number of increasingly senior roles at Roche, McKinsey and MPM Capital in Cambridge, USA.

JR graduated from FU University Berlin (Germany) and gained his Ph.D. in Molecular Immunology from Freiburg University (Germany).

Ariceum Therapeutics

Per Samuelsson

Non-Executive Director

Per is a partner at HealthCap. HealthCap is a family of venture capital funds investing globally in life sciences. With more than EUR 1.2 billion raised since its start in 1996, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe. Prior to joining HealthCap as a partner in 2000, Per gained over 15 years of investment banking experience, mainly with ABB Aros Securities in Sweden. In his last position with ABB Aros Securities, as a Director in the firm’s corporate finance department, he specialized in the areas of merger transactions, initial public offerings and equity incentive programs. Prior to this Per was Head of Research, also at ABB Aros Securities.

Per received his M.Sc. in Engineering from the Institute of Technology in Linköping.

Ariceum Therapeutics

Martin Münchbach, PhD

Non-Executive Director

Martin is a founding partner of Pureos Bioventures where he holds the position of Managing Partner. He has been a venture capital investor since 1999, investing in life science companies across all stages and types. Prior to Pureos, he was senior investment advisor private equity at Bellevue Asset Management. Martin’s most successful investments and board assignments include Radius Health, Molecular Partners, Optimer, Axovan and Glycart. In addition to Ariceum, Martin is currently a Board member at Ypsomed Holding, Alentis Therapeutics, binX Health and River Renal.

Martin obtained his PhD in Protein Chemistry and his MAS in Management, Technology and Economics from ETH Zurich.

Ariceum Therapeutics

© Ariceum Therapeutics

Website by FisherPaul

  • Imprint
  • Privacy Policy

Scroll to top Scroll to top Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settings

Cookie and Privacy Settings



How we use cookies
Essential Website Cookies
Google Analytics Cookies
Other external services
Other cookies
Privacy Policy
How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.